Send article: FDA and the Paul Ehrlich Institute Approve Pluristem's Regulatory Submissions in Support of a Phase I/II Clinical Trial Utilizing PLX-PAD for Peripheral Artery Disease

Business Wire, May 6, 2008  

Recipient's email

Your name

Your email

Comments